EnsoData has expanded its capabilities in sleep apnoea screening and diagnosis with the acquisition of diagnostic technology from Resonea.

This move aims to reduce the cost and improve the systematic screening of sleep apnea across broad patient populations, addressing a condition that is often underdiagnosed yet exacerbates serious health issues such as cardiovascular and neurodegenerative diseases, and metabolic disorders.

EnsoData CEO Justin Mortara said: “This is another step toward simplifying access to sleep care, helping to get more patients with sleep disorders diagnosed and ultimately connected with therapy.

“As a leader in healthcare AI solutions, EnsoData’s device-agnostic approach using pulse oximeters (PPG) and now smartphones supports our strategy to deploy flexible solutions that can easily scale to address the unmet clinical needs for sleep testing in the US and globally.”

The acquired technology introduces acoustic flow and microphone data channels, which will be integrated into a US Food and Drug Administration (FDA)-cleared mobile application.

This approach allows for the pre-screening of patients for sleep apnoea and enhances the home sleep testing diagnostic capabilities.

The mobile app records auditory data at the time of sleep, securely transfers it to the cloud and performs a breath-by-breath acoustic analysis to identify sleep apnoea events or other disorders.

Patients can use their existing smartphones to facilitate this mobile-first, data-driven pre-screening process without the need for medical hardware.

In a diagnostic setting, sleep physicians will now have access to these channels for conducting sleep studies at home.

By combining a pulse oximeter cleared by the FDA with the mobile-based microphone and acoustic flow, clinicians can deepen their analysis and reporting capabilities available in EnsoSleep PPG, achieving a broader scope of quality clinical data.

This new technology enables physicians to deliver more personalised sleep apnoea diagnoses and tailor patient experiences when initiating treatment.

EnsoData expects the initial commercial availability of these new capabilities in the US within this year.

The companies have not disclosed the financial terms of the deal.